Lexology September 9, 2024
On September 7, China’s Ministry of Commerce, the National Health Commission, and the National Medical Products Administration issued a notice announcing the expansion of pilot programs for foreign investment in the healthcare sector (the “Notice”), marking a significant relaxation of China’s long-standing restrictions on foreign investment in the healthcare industry.
The expansion mainly impacts the following two areas:
1. Biotechnology
Starting from September 7, 2024, foreign-invested enterprises will be allowed to engage in the development and application of human stem cell and gene diagnostic and treatment technologies in Beijing Free Trade Zone, Shanghai Free Trade Zone, Guangdong Free Trade Zone, and Hainan Free Trade Port. These activities are aimed at facilitating the registration, listing, and production of related products, which,...
Today's Sponsors
Today's Sponsor